Male doctors called my cancer incurable. A female doctor showed it wasn't

MollyFergusonforSTATWhenmysilentassassinemergedlastautumn,Ipressedmysurgeonabouttheprognosisforaform OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand




focus

author：leisure time    Page View：129
close-up of psoriasis on a hand. -- biotech coverage from STAT
A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

advertisement

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Ethical issues complicate the benefits of medical crowdfunding
Next article： Dobbs anniversary: the lost opportunity of abortion as health care